EW
CLVS

Evoke Wealth’s Clovis Oncology, Inc. CLVS Stock Holding History

Evoke Wealth’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,000
Closed -$27K – 1281
2021
Q4 		$27K Hold
10,000
– – ﹤0.01% 633
2021
Q3 		$44K Hold
10,000
– – ﹤0.01% 527
2021
Q2 		$58K Hold
10,000
– – ﹤0.01% 511
2021
Q1 		$70K Hold
10,000
– – ﹤0.01% 415
2020
Q4 		$48K Hold
10,000
– – ﹤0.01% 383
2020
Q3 		$58K Hold
10,000
– – ﹤0.01% 340
2020
Q2 		$68K Hold
10,000
– – 0.01% 315
2020
Q1 		$63.6K Buy
+10,000
New +$80.2K 0.01% 317

Other funds holding CLVS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Evoke Wealth's CLVS Position: Q1 2022 in Review

Evoke Wealth sold out of Clovis Oncology, Inc. (CLVS) in Q1 2022, closing a stake of 10,000 shares — an estimated $27K sold.

Evoke Wealth first reported a position in CLVS in Q1 2020 and held it in 8 quarters. The position peaked at $70K in Q1 2021. 153 funds tracked by Wall St. Rank hold CLVS as of Q1 2022.

  • Evoke Wealth reported no remaining Clovis Oncology, Inc. position as of Q1 2022 after selling out during the quarter.
  • Evoke Wealth sold 10,000 Clovis Oncology, Inc. shares in Q1 2022, an estimated $27K.
  • Evoke Wealth first reported a position in Clovis Oncology, Inc. in Q1 2020 and held it in 8 quarters.
  • Evoke Wealth's Clovis Oncology, Inc. position peaked at $70K in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2022.

Based on Evoke Wealth's 13F filing for Q1 2022, filed 10 May 2022.